Albeit a fraction of MZL patients present MYD88 abnormalities [2,10,11,12,13,14], the prevalence of these mutations, in particular the L265P, is much higher in LPL, [2,10,11,12,13,14,15,16,17] and we cannot rule out the possibility that the cell line derives from a LPL rather than from MZL. The gene discussed is LPL; the disease is marginal zone lymphoma.